Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Youngtong-gu, Suwon, 443-721, South Korea.
Lung Cancer. 2009 Dec;66(3):359-64. doi: 10.1016/j.lungcan.2009.03.002. Epub 2009 Mar 31.
We evaluated the clinical significance of angiopoietins and vascular endothelial growth factor (VEGF) in patients with resected early stage lung cancer.
The study enrolled 101 patients with completely resected non-small cell lung cancer (NSCLC) of stage I or II, along with 70 healthy volunteers. Serum concentrations of angiopoietin-1, angiopoietin-2, and VEGF were measured with an ELISA. Immunohistochemical expression of angiopoietin-1 was compared with the microvessel density on the lung cancer tissues.
The patients had lower serum angiopoietin-1 (32.1+/-9.9 ng/mL vs. 39.0+/-10.8 ng/mL, p<0.001), higher angiopoietin-2 (1949.2+/-1099.4 pg/mL vs. 1498.6+/-650.0 pg/mL, p<0.01), and higher VEGF (565.1+/-406.3 pg/mL vs. 404.6+/-254.8 pg/mL, p<0.01) levels than the controls. The angiopoietin-2 level was higher in stage II than in stage I patients (p<0.05). The levels of angiopoietin-1 (r=0.28) and angiopoietin-2 (r=0.36) each correlated with the VEGF level. Patients with a higher level of angiopoietin-1 (> or =31.2 ng/mL) had better disease-specific and relapse-free survival than those with a lower angiopoietin-1 level (<31.2 ng/mL). Angiopoietin-1 expression negatively correlated with the microvessel density.
Serum angiopoietin-1 is a potential marker for predicting postoperative survival and recurrence in patients with early stage NSCLC.
我们评估了血管生成素和血管内皮生长因子（VEGF）在早期肺癌患者中的临床意义。
本研究纳入了 101 例完全切除的Ⅰ期或Ⅱ期非小细胞肺癌（NSCLC）患者和 70 名健康志愿者。通过 ELISA 检测血清血管生成素-1、血管生成素-2 和 VEGF 的浓度。比较血管生成素-1 在肺癌组织中的免疫组化表达与微血管密度。
患者的血清血管生成素-1 水平（32.1+/-9.9ng/mL vs. 39.0+/-10.8ng/mL，p<0.001）较低，血管生成素-2（1949.2+/-1099.4pg/mL vs. 1498.6+/-650.0pg/mL，p<0.01）和 VEGF（565.1+/-406.3pg/mL vs. 404.6+/-254.8pg/mL，p<0.01）水平较高。Ⅱ期患者的血管生成素-2 水平高于Ⅰ期患者（p<0.05）。血管生成素-1 水平（r=0.28）和血管生成素-2 水平（r=0.36）均与 VEGF 水平相关。血管生成素-1 水平较高（>或=31.2ng/mL）的患者的疾病特异性和无复发生存率优于血管生成素-1 水平较低的患者（<31.2ng/mL）。血管生成素-1 的表达与微血管密度呈负相关。
血清血管生成素-1 可能是预测早期 NSCLC 患者术后生存和复发的潜在标志物。
